Company Overview

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company dedicated to investigating potential therapeutics for cancer and inflammatory dermatoses.

Recent Financial News

Date   Headline
May 18, 2020 Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
Apr 29, 2020 Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Apr 16, 2020 Provectus Announces PV-10® Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
Mar 17, 2020 PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
Dec 12, 2019 Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019

Investor Contacts

Our Contact Form Mailing Address

Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Provectus Biopharmaceuticals, Inc.
10025 Investment Drive, Suite 250
Knoxville, TN 37932
Investor Relations Media Relations

Provectus Biopharmaceuticals, Inc.
Email: investorrelations@pvct.com
Phone: +1 (866) 594-5999 x1

Provectus Biopharmaceuticals, Inc.
E-mail: mediarelations@pvct.com
Phone: +1 (866) 594-5999 x4
Transfer Agent

(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
E-mail: shareholder@broadridge.com
Telephone: +1 (877) 830-4936
Fax: +1 (215) 553-5402

Stock Performance

Today's Open 0.04
Volume 40,622
Day Range 0.04 - 0.05
52 Week Range 0.03 - 0.07
Bid/Ask 0.04 / 0.05
Bid/Ask Size 10,000 X 75,000
Previous Close 0.04
Market Cap 17.42 million
Shares Outstanding 390.69 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -0.02
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
May 13, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 05, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 12, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 08, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl